BioScrip Inc. (NASDAQ:BIOS)’s share price traded up 3.5% during mid-day trading on Monday . The company traded as high as $2.68 and last traded at $2.68, with a volume of 527,650 shares traded. The stock had previously closed at $2.59.

Separately, Zacks Investment Research cut shares of BioScrip from a “hold” rating to a “sell” rating in a research report on Wednesday, May 11th.

The stock’s 50-day moving average is $2.61 and its 200 day moving average is $2.28. The firm’s market capitalization is $183.64 million.

BioScrip (NASDAQ:BIOS) last released its quarterly earnings results on Thursday, May 5th. The company reported ($0.17) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.12) by $0.05. The firm had revenue of $238.50 million for the quarter, compared to analysts’ expectations of $232.38 million. During the same period in the prior year, the firm earned ($0.17) earnings per share. The firm’s revenue was down 2.4% on a year-over-year basis. On average, equities analysts predict that BioScrip Inc. will post ($0.20) earnings per share for the current year.

In other news, Director David W. Golding bought 12,500 shares of BioScrip stock in a transaction that occurred on Friday, June 17th. The stock was bought at an average cost of $2.48 per share, with a total value of $31,000.00. Following the acquisition, the director now owns 42,500 shares of the company’s stock, valued at approximately $105,400. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Coliseum Capital Management, L bought 4,200,000 shares of BioScrip stock in a transaction that occurred on Wednesday, June 22nd. The stock was purchased at an average cost of $2.00 per share, with a total value of $8,400,000.00. The disclosure for this purchase can be found here.

A hedge fund recently raised its stake in BioScrip stock. Diamond Hill Capital Management Inc. boosted its stake in BioScrip Inc. (NASDAQ:BIOS) by 2.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 3,055,476 shares of the company’s stock after buying an additional 74,757 shares during the period. Diamond Hill Capital Management Inc. owned approximately 4.44% of BioScrip worth $5,347,000 as of its most recent filing with the SEC.

BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.